Clinical Trial Update: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the combination of baricitinib with an anti-TNF therapy for rheumatoid arthritis; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Baricitinib (Olumiant) (baricitinib)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Rheumatoid Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING